Kazia Therapeutics Limited ADR (KZIA) concluded trading on Wednesday at a closing price of $0.32, with 20.42 million shares of worth about $6.53 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -65.97% during that period and on Wednesday the price saw a loss of about -20.61%. Currently the company’s common shares owned by public are about 23.63M shares, out of which, 23.62M shares are available for trading.
However, the stock later moved at a day high price of 0.4498, or with a loss of -20.61%. Stock saw a price change of 13.59% in past 5 days and over the past one month there was a price change of -9.97%. Year-to-date (YTD), KZIA shares are showing a performance of -28.30% which decreased to -64.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $1.68 during that period. The average intraday trading volume for Kazia Therapeutics Limited ADR shares is 233.34K. The stock is currently trading 2.33% above its 20-day simple moving average (SMA20), while that difference is down -12.24% for SMA50 and it goes to -61.05% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Kazia Therapeutics Limited ADR (NASDAQ: KZIA) currently have 23.63M outstanding shares and institutions hold larger chunk of about 20.66% of that.
The stock has a current market capitalization of $7.45M and its 3Y-monthly beta is at 2.17. It has posted earnings per share of -$0.83 in the same period. It has Quick Ratio of 1.42 while making debt-to-equity ratio of 0.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KZIA, volatility over the week remained 30.41% while standing at 20.38% over the month.
Analysts are in expectations that Kazia Therapeutics Limited ADR (KZIA) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on October 14, 2021 offering a Buy rating for the stock and assigned a target price of $18 to it. Coverage by H.C. Wainwright stated Kazia Therapeutics Limited ADR (KZIA) stock as a Buy in their note to investors on January 05, 2021, suggesting a price target of $17 for the stock.
